Johnson, SR; Gladman, DD; Brunner, HI; Isenberg, D; Clarke, AE; Barber, MR W; Arnaud, L; Fortin, PR; Mosca, M; Voskuyl, A; et al.
Evaluating the construct of damage in systemic lupus erythematosus.
Arthritis Care and Research.
2021.
Balmuri, N; Soulsby, WD; Cooley, V; Gerber, L; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; et al.
Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis.
Pediatric Rheumatology.
2021;
19.
Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; Abel, N; et al.
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Pediatric Rheumatology.
2021;
19.
Dave, I; Estroff, B; Gergely, T; Rostad, CA; Ponder, LA; McCracken, C; Prahalad, S; Abel, N; Abulaban, K; Adams, A; et al.
Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study.
Journal of Rheumatology.
2021;
48:1856-1862.
Ruperto, N; Brunner, HI; Synoverska, O; Ting, TV; Mendoza, CA; Spindler, A; Vyzhga, Y; Marzan, K; Grebenkina, L; Tirosh, I; et al.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
The Lancet.
2021;
398:1984-1996.
van Vollenhoven, RF; Bertsias, G; Doria, A; Isenberg, D; Morand, E; Petri, MA; Pons-Estel, BA; Rahman, A; Ugarte-Gil, MF; Voskuyl, A; et al.
2021 DORIS definition of remission in SLE: final recommendations from an international task force.
Lupus Science and Medicine.
2021;
8.
Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; et al.
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Rheumatology.
2021;
60:4495-4507.
Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; et al.
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Rheumatology.
2021;
60:4568-4580.
Schultz, K; Divanovic, A; Towe, C; Miethke, A; Wusik, K; Hammill, A; Brunner, H.
Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing.
Arthritis Care and Research.
2021;
73:1379-1386.
Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; Abel, N; Abulaban, K; Adams, A; Adams, M; et al.
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Arthritis and Rheumatology.
2021;
73:1910-1920.
Kimura, Y; Schanberg, LE; Tomlinson, GA; Riordan, ME; Dennos, AC; Del Gaizo, V; Murphy, KL; Weiss, PF; Natter, MD; Feldman, BM; et al.
Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Arthritis and Rheumatology.
2021;
73:1898-1909.
Brunner, HI; Abud-Mendoza, C; Mori, M; Pilkington, CA; Syed, R; Takei, S; Viola, DO; Furie, RA; Navarra, S; Zhang, F; et al.
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
RMD Open.
2021;
7.
Brunner, HI; Chen, C; Bovis, F; De Benedetti, F; Espada, G; Joos, R; Akikusa, J; Chaitow, J; Boteanu, AL; Kimura, Y; et al.
Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
Arthritis Care and Research.
2021;
73:1264-1274.
Mannion, ML; Xie, F; Horton, DB; Ringold, S; Correll, CK; Dennos, A; Beukelman, T; Abel, N; Abulaban, K; Adams, A; et al.
Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Journal of Rheumatology.
2021;
48:1322-1329.
Avar-Aydin, PO; Schultz, K; Brunner, HI.
Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus.
Outcome Measures and Metrics in Systemic Lupus Erythematosus.
2021.
Lovell, DJ; Brunner, HI.
Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis.
Arthritis Care and Research.
2021;
73:921-923.
Ruperto, N; Brunner, HI; Tzaribachev, N; Vega-Cornejo, G; Louw, I; Cimaz, R; Dare, J; Espada, G; Faugier, E; Ferrandiz, M; et al.
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis.
Journal of Rheumatology.
2021;
48:1073-1081.
Cody, EM; Bennett, MR; Gulati, G; Ma, Q; Altaye, M; Devarajan, P; Brunner, HI.
Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity.
Kidney International Reports.
2021;
6:1949-1960.
Rumsey, DG; Lougee, A; Matsouaka, R; Collier, DH; Schanberg, LE; Schenfeld, J; Shiff, NJ; Stoll, ML; Stryker, S; Weiss, PF; et al.
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis.
Arthritis Care and Research.
2021;
73:940-946.
Dominguez, D; Kamphuis, S; Beyene, J; Wither, J; Harley, JB; Blanco, I; Vila-Inda, C; Brunner, H; Klein-Gitleman, M; McCurdy, D; et al.
Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus.
Journal of Rheumatology.
2021;
48:852-858.
Aljaberi, N; Nguyen, K; Strahle, C; Merritt, A; Mathur, A; Brunner, HI.
Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults.
Arthritis Care and Research.
2021;
73:580-585.
Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI.
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.
RMD Open.
2021;
7.
Brunner, HI; Ruperto, N; Zuber, Z; Cuttica, R; Keltsev, V; Xavier, RM; Burgos-Vargas, R; Penades, IC; Silverman, ED; Espada, G; et al.
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Arthritis and Rheumatology.
2021;
73:530-541.
Quartier, P; Alexeeva, E; Constantin, T; Chasnyk, V; Wulffraat, N; Palmblad, K; I. Brunner, H; Marzan, K; Schneider, R; Horneff, G; et al.
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
Arthritis and Rheumatology.
2021;
73:336-346.
Reighard, SD; Krishnamurthy, D; Cevik, H; Ochayon, DE; Ali, A; Seelamneni, H; Brunner, HI; Waggoner, SN.
Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease.
Cytotherapy.
2021;
23:37-45.